SavedAdd your journal

Journals / Journal of Experimental and Clinical Medicine / 2026 / Volume: 43 Issue: 3

The protective paradox: APOE3ch and disease-associated microglia regulating calcium signaling impact the niche in Alzheimer resilience

Benarjee Veera Mani Kishore Boddeda(Vignan Institute of Phamaceutical Technology)0009-0002-5635-6391
Vinodkumar Mugada(Vignan Institute of Pharmaceutical Technology)0000-0002-9364-9874
Mahaboobunnisa Khan(Vignan Institute of Pharmaceutical Technology)0009-0009-2157-789X
Srinivasa Rao Yarguntla(Vignan Institute of Pharmaceutical Technology)0000-0002-8803-9668
Pages
—
Publication Date
2026-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therapeutic translation will require genotype-sensitive designs, human-relevant models, spatiotemporal resolution, validated biomarkers, and careful safety evaluation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Alzheimer’s disease (AD) resilience refers to the preservation of cognitive function despite substantial neuropathological burden.
📊
Key Findings & Data:Among the most informative examples is the APOE3-Christchurch (APOE3ch; R136S) variant, which has been associated with delayed clinical expression of autosomal dominant AD despite extensive amyloid deposition.
💡
Conclusion & Impact:Therapeutic translation will require genotype-sensitive designs, human-relevant models, spatiotemporal resolution, validated biomarkers, and careful safety evaluation.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:APOE3-Christchurch (APOE3ch) · proteoglycans of heparan sulphate · microglial calcium signaling

Abstract

Alzheimer’s disease (AD) resilience refers to the preservation of cognitive function despite substantial neuropathological burden. Among the most informative examples is the APOE3-Christchurch (APOE3ch; R136S) variant, which has been associated with delayed clinical expression of autosomal dominant AD despite extensive amyloid deposition. This review examines APOE3ch as a natural model for investigating protective biology in AD, with particular attention to ApoE–heparan sulfate proteoglycan (HSPG) interactions, tau handling, plaque microenvironment dynamics, disease-associated microglia (DAM), and microglial calcium (Ca²⁺) signaling. Current evidence supports a role for APOE3ch in weakening ApoE–HSPG interactions and modifying tau-related pathological processes. HSPG sulfation patterns also influence tau internalization and proteopathic spread, while TREM2-dependent DAM responses may exert stage-specific protective or harmful effects. Microglial Ca²⁺ signaling, including store-operated calcium entry through Orai/STIM pathways, is increasingly recognized as a key regulator of microglial motility, phagocytosis, cytokine release, and transcriptional programming. However, direct evidence linking APOE3ch-mediated HSPG disruption to altered microglial Ca²⁺ dynamics remains lacking. Therefore, this review proposes the APOE3ch–HSPG–Ca²⁺–DAM axis as a hypothesis-generating framework rather than an established mechanistic pathway. We highlight current evidence, identify inferential gaps, discuss alternative mechanisms of resilience, and outline experimental strategies needed to test whether APOE3ch-associated extracellular remodeling influences microglial Ca²⁺ signaling and protective DAM states. Therapeutic translation will require genotype-sensitive designs, human-relevant models, spatiotemporal resolution, validated biomarkers, and careful safety evaluation.

🔖

Cite This Article

Boddeda, B. V. M. K., Mugada, V., Khan, M., Yarguntla, S. R. (2026). The protective paradox: APOE3ch and disease-associated microglia regulating calcium signaling impact the niche in Alzheimer resilience. Journal of Experimental and Clinical Medicine, Volume: 43 Issue: 3. https://ajindex.com/articles/1422497

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (50)

  1. de Vries LE, Huitinga I, Kessels HW, Swaab DF, Verhaagen J. The concept of resilience to Alzheimer's disease: current definitions and cellular and molecular mechanisms. Mol Neurodegener. 2024;19(1):33. https://doi.org/10.1186/s13024-024-00719-7
  2. Neuner SM, Telpoukhovskaia M, Menon V, O'Connell KMS, Hohman TJ, Kaczorowski CC. Translational approaches to understanding resilience to Alzheimer's disease. Trends Neurosci. 2022;45(5):369-383. https://doi.org/10.1016/j.tins.2022.02.005
  3. Phongpreecha T, Godrich D, Berson E, Espinosa C, Kim Y, Cholerton B, et al. Quantitative estimate of cognitive resilience and its medical and genetic associations. Alz Res Ther. 2023;15(1):192. https://doi.org/10.1186/s13195-023-01329-z
  4. O'Neill N, Stein TD, Olayinka OA, Empawi JA, Hu J, Tong T, et al. Cognitive resilience to Alzheimer's disease characterized by cell-type abundance. Alzheimers Dement. 2024;20(10):6910-6921. https://doi.org/10.1002/alz.14187
  5. Arboleda-Velasquez JF, Lopera F, O'Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680-1683. https://doi.org/10.1038/s41591-019-0611-3
  6. Perez-Corredor P, Arevalo-Alquichire S, Mazzarino RC, O'Hare M, Muriel-Torres AF, Vacano GN, et al. ApoE3 Christchurch and tau interaction as a protective mechanism against Alzheimer's disease. Alzheimers Dement. 2025;21(7):e70396. https://doi.org/10.1002/alz.70396
  7. Sepulveda-Falla D, Sanchez JS, Almeida MC, Boassa D, Acosta-Uribe J, Vila-Castelar C, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathol. 2022;144(3):589-601. https://doi.org/10.1007/s00401-022-02467-8
  8. Chen Y, Holtzman DM. New insights into innate immunity in Alzheimer's disease: from APOE protective variants to therapies. Trends Immunol. 2024;45(10):768-782. https://doi.org/10.1016/j.it.2024.08.001
  9. Marino C, Perez-Corredor P, O'Hare M, Heuer A, Chmielewska N, Gordon H, et al. APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation. Alzheimers Dement. 2024;20(2):819-836. https://doi.org/10.1002/alz.13436
  10. Mah D, Zhao J, Liu X, Zhang F, Liu J, Wang L, et al. The sulfation code of tauopathies: heparan sulfate proteoglycans in the prion like spread of tau pathology. Front Mol Biosci. 2021;8:671458. https://doi.org/10.3389/fmolb.2021.671458
  11. Zhu Y, Gandy L, Zhang F, Liu J, Wang C, Blair LJ, et al. Heparan sulfate proteoglycans in tauopathy. Biomolecules. 2022;12(12):1792. https://doi.org/10.3390/biom12121792
  12. Rauch JN, Chen JJ, Sorum AW, Miller GM, Sharf T, See SK, et al. Tau internalization is regulated by 6-O sulfation on heparan sulfate proteoglycans (HSPGs). Sci Rep. 2018;8(1):6382. https://doi.org/10.1038/s41598-018-24904-z
  13. Schultheis N, Connell A, Kapral A, Becker RJ, Mueller R, Shah S, et al. Altering heparan sulfate suppresses cell abnormalities and neuron loss in Drosophila presenilin model of Alzheimer disease. iScience. 2024;27(7):110256. https://doi.org/10.1016/j.isci.2024.110256
  14. Tran KM, Kwang NE, Butler CA, Gomez-Arboledas A, Kawauchi S, Mar C, et al. APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology. Mol Neurodegener. 2025;20(1):9. https://doi.org/10.1186/s13024-024-00793-x
  15. Bachiller S, Jiménez-Ferrer I, Paulus A, Yang Y, Swanberg M, Deierborg T, et al. Microglia in neurological diseases: a road map to brain-disease dependent-inflammatory response. Front Cell Neurosci. 2018;12:488. https://doi.org/10.3389/fncel.2018.00488
  16. Samant RR, Standaert DG, Harms AS. The emerging role of disease-associated microglia in Parkinson's disease. Front Cell Neurosci. 2024;18:1476461. https://doi.org/10.3389/fncel.2024.1476461
  17. Yin Y, Yang H, Li R, Wu G, Qin Q, Tang Y. A systematic review of the role of TREM2 in Alzheimer's disease. Chin Med J. 2024;137(14):1684-1694. https://doi.org/10.1097/CM9.0000000000003000
  18. Zhao N, Qiao W, Li F, Ren Y, Zheng J, Martens YA, et al. Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia. J Exp Med. 2022;219(12):e20212479. https://doi.org/10.1084/jem.20212479
  19. McFarland KN, Chakrabarty P. Microglia in Alzheimer's disease: a key player in the transition between homeostasis and pathogenesis. Neurotherapeutics. 2022;19(1):186-208. https://doi.org/10.1007/s13311-021-01179-3
  20. Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer's disease. Cell. 2017;169(7):1276-1290.e17. https://doi.org/10.1016/j.cell.2017.05.018
  21. Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques. Nat Commun. 2015;6:6176. https://doi.org/10.1038/ncomms7176
  22. Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, Amit I. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell. 2018;173(5):1073-1081. https://doi.org/10.1016/j.cell.2018.05.003
  23. Nevelchuk S, Brawek B, Schwarz N, Valiente-Gabioud A, Wuttke TV, Kovalchuk Y, et al. Morphotype-specific calcium signaling in human microglia. J Neuroinflammation. 2024;21(1):175. https://doi.org/10.1186/s12974-024-03169-6
  24. Korshunov KS, Prakriya M. Store-operated calcium channels in the nervous system. Annu Rev Physiol. 2025;87(1):173-199. https://doi.org/10.1146/annurev-physiol-022724-105330
  25. Tsujikawa S, DeMeulenaere KE, Centeno MV, Ghazisaeidi S, Martin ME, Tapies MR, et al. Regulation of neuropathic pain by microglial Orai1 channels. Sci Adv. 2023;9(4):eade7002. https://doi.org/10.1126/sciadv.ade7002
  26. Tang W, Peng J, Chen L, Yu C, Wang Y, Zou F, et al. Lead inhibits microglial cell migration via suppression of store-operated calcium entry. Toxicol Lett. 2024;393:69-77. https://doi.org/10.1016/j.toxlet.2024.01.011
  27. Umpierre AD, Li B, Ayasoufi K, Simon WL, Zhao S, Xie M, et al. Microglial P2Y6 calcium signaling promotes phagocytosis and shapes neuroimmune responses in epileptogenesis. Neuron. 2024;112(12):1959-1977.e10. https://doi.org/10.1016/j.neuron.2024.03.017
  28. Blevins HM, Xu Y, Biby S, Zhang S. The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci. 2022;14:879021. https://doi.org/10.3389/fnagi.2022.879021
  29. Wendimu MY, Alqinyah M, Vella S, Dean P, Almutairi F, Davila-Rivera R, et al. RGS10 physically and functionally interacts with STIM2 and requires store-operated calcium entry to regulate pro-inflammatory gene expression in microglia. Cell Signal. 2021;83:109974. https://doi.org/10.1016/j.cellsig.2021.109974
  30. Chen Y, Song S, Parhizkar S, Lord J, Zhu Y, Strickland MR, et al. APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread. Cell. 2024;187(2):428-445.e20. https://doi.org/10.1016/j.cell.2023.11.029
  31. Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022;17(1):72. https://doi.org/10.1186/s13024-022-00574-4
  32. Snow AD, Cummings JA, Lake T. The unifying hypothesis of Alzheimer's disease: heparan sulfate proteoglycans/glycosaminoglycans are key as first hypothesized over 30 years ago. Front Aging Neurosci. 2021;13:710683. https://doi.org/10.3389/fnagi.2021.710683
  33. Ozsan McMillan I, Li JP, Wang L. Heparan sulfate proteoglycan in Alzheimer's disease: aberrant expression and functions in molecular pathways related to amyloid-β metabolism. Am J Physiol Cell Physiol. 2023;324(4):C893-C909. https://doi.org/10.1152/ajpcell.00247.2022
  34. Rangaraju S, Dammer EB, Raza SA, Rathakrishnan P, Xiao H, Gao T, et al. Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated microglia in Alzheimer's disease. Mol Neurodegener. 2018;13(1):24. https://doi.org/10.1186/s13024-018-0254-8
  35. Miao J, Ma H, Yang Y, Liao Y, Lin C, Zheng J, et al. Microglia in Alzheimer's disease: pathogenesis, mechanisms, and therapeutic potentials. Front Aging Neurosci. 2023;15:1201982. https://doi.org/10.3389/fnagi.2023.1201982
  36. Li Y, Macyczko JR, Liu CC, Bu G. ApoE4 reduction: an emerging and promising therapeutic strategy for Alzheimer's disease. Neurobiol Aging. 2022;115:20-28. https://doi.org/10.1016/j.neurobiolaging.2022.03.011
  37. Poblano J, Castillo-Tobías I, Berlanga L, Tamayo-Ordoñez MC, Del Carmen Rodríguez-Salazar M, Silva-Belmares SY, et al. Drugs targeting APOE4 that regulate beta-amyloid aggregation in the brain: therapeutic potential for Alzheimer's disease. Basic Clin Pharmacol Toxicol. 2024;135(3):237-249. https://doi.org/10.1111/bcpt.14055
  38. Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model. J Exp Med. 2020;217(9):e20200785. https://doi.org/10.1084/jem.20200785
  39. Long H, Simmons A, Mayorga A, Burgess B, Nguyen T, Budda B, et al. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease. Alz Res Ther. 2024;16(1):235. https://doi.org/10.1186/s13195-024-01599-1
  40. Piers TM, Cosker K, Mallach A, Johnson GT, Guerreiro R, Hardy J, et al. A locked immunometabolic switch underlies TREM2 R47H loss of function in human iPSC-derived microglia. FASEB J. 2020;34(2):2436-2450. https://doi.org/10.1096/fj.201902447R
  41. Garaschuk O, Verkhratsky A. Calcium signalling in microglia. Adv Neurobiol. 2024;37:123-133. https://doi.org/10.1007/978-3-031-55529-9_7
  42. McLarnon JG. Microglial store-operated calcium signaling in health and in Alzheimer's disease. Curr Alzheimer Res. 2020;17(12):1057-1064. https://doi.org/10.2174/1567205018666210119143817
  43. Litvinchuk A, Huynh TV, Shi Y, Jackson RJ, Finn MB, Manis M, et al. Apolipoprotein E4 reduction with antisense oligonucleotides decreases neurodegeneration in a tauopathy model. Ann Neurol. 2021;89(5):952-966. https://doi.org/10.1002/ana.26043
  44. Williams T, Borchelt DR, Chakrabarty P. Therapeutic approaches targeting apolipoprotein E function in Alzheimer's disease. Mol Neurodegener. 2020;15(1):8. https://doi.org/10.1186/s13024-020-0358-9
  45. Pascoal TA, Aguzzoli CS, Lussier FZ, Crivelli L, Suemoto CK, Fortea J, et al. Insights into the use of biomarkers in clinical trials in Alzheimer's disease. EBioMedicine. 2024;108:105322. https://doi.org/10.1016/j.ebiom.2024.105322
  46. Cummings J, Kinney J. Biomarkers for Alzheimer's disease: context of use, qualification, and roadmap for clinical implementation. Medicina. 2022;58(7):952. https://doi.org/10.3390/medicina58070952
  47. Nelson MR, Liu P, Agrawal A, et al. The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration and neuroinflammation. Nat Neurosci. 2023;26:2104-2121. https://doi.org/10.1038/s41593-023-01480-8
  48. Peng J, Pan BX. Microglial calcium: an exquisite sensor for neuronal activity. Neurosci Bull. 2021;37(6):582-584. https://doi.org/10.1007/s12264-021-00655-2
  49. Zhang I, Hu H. Store-operated calcium channels in physiological and pathological states of the nervous system. Front Cell Neurosci. 2020;14:600758. https://doi.org/10.3389/fncel.2020.600758
  50. Liao F, Li A, Xiong M, Bien-Ly N, Jiang H, Zhang Y, et al. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest. 2018;128(5):2144-2155. https://doi.org/10.1172/JCI96429